Artificial intelligence is rapidly changing how life sciences companies create, manage, deliver, and use information.
AI can summarize complex information, generate first drafts, answer questions, recommend content, and help sales teams prepare for customer engagements.
Across the industry, organizations are already exploring AI for everything from content creation to medical and regulatory review. But in a regulated industry, the ability to use the latest technology doesn't automatically mean that everyone should.
The future of AI-powered sales enablement will depend not only on what AI can do, but on whether organizations can harness it responsibly – ensuring that the information used in the field is accurate, current, approved, and appropriate for the audience.
This isn't a hypothetical future. In a May 2026 article, Deloitte described AI as a potential "copilot" for biopharma field teams, helping representatives navigate complex information and surface relevant insights for customer interactions.
At the same time, in a July 2026 article, IQVIA points to a different challenge created by AI: pharmaceutical organizations can now generate highly targeted content and multiple content variations at unprecedented speed, shifting the bottleneck toward timely review and approval.
Put those two developments together and an important question emerges: As AI makes content easier to create and easier to find, how do organizations make sure the field is using the right content?
Marketing teams have always faced a familiar problem: there is never enough time to create all the content the sales teams want - AI changes that equation.
A marketer can use AI to create a draft presentation, summarize a clinical study, adapt messaging for a particular audience, or turn existing material into a new format in minutes rather than hours. That can be enormously valuable, but creating content is only one part of the problem.
In life sciences, content may need to go through medical, legal, and regulatory review before it can be presented or given to customers. Claims need supporting evidence, language matters, it needs to be approved, and outdated materials need to be removed. All of this is relevant because different products, markets, and audiences may require different versions.
The challenge isn't simply creating more content. It's making sure the content is validated – and that reps are using the right content for the right audience and purpose.
The temptation with AI is to think of it as the new source of truth, but in practice it definitely shouldn't be. AI can be extremely good at finding, summarizing, organizing, and recommending information. But the source and context of that information still matters.
A life sciences organization should be able to answer basic questions about every piece of customer-facing content:
• Is it approved?
• Who approved it?
• When was it approved?
• Is it still current?
• Which product or indication does it support?
• Which markets or audiences can use it?
• Has a newer version replaced it?
• Can the field team access it offline?
• Can the organization see how it is being used?
Those questions don't disappear because AI has entered the picture - if anything, they become more important.
The most useful role for AI in sales enablement today may not be creating completely new content, it may be in helping sales professionals navigate the enormous amount of existing approved content their organizations already have.
Imagine a representative preparing for a meeting with an HCP. Instead of searching through hundreds or thousands of files, the rep could ask:
"Show me the most relevant approved content for this customer."
AI could identify the appropriate materials based on the product, audience, stage of the conversation, and other relevant context.
But there is an important distinction: AI recommends. Governance decides.
For life sciences, AI is most useful when it works from a controlled content environment – not an uncontrolled collection of documents scattered across shared drives, email, cloud storage, and personal devices. That distinction could become one of the defining characteristics of an effective AI-powered sales enablement ecosystem.
Personalization is another area where AI can have tremendous potential.
Sales teams want to tailor conversations to individual customers. They want to emphasize the information that matters most to a particular audience and make complex scientific information easier to understand. AI can help make that process faster, but personalization in a regulated environment has significant boundaries.
There is a significant difference between:
"Help me find the approved content most relevant to this customer."
and:
"Create a new claim for this customer."
The first can improve productivity while maintaining control. The second can create an entirely different set of risks. The goal shouldn't be to eliminate personalization. It should be to make personalization possible within a controlled framework.
For life sciences organizations, AI readiness isn't necessarily about having the newest AI feature. It's about having the foundation that allows AI to work responsibly. That foundation includes a single source of truth. Sales and marketing teams need confidence that they are accessing the current version of approved content.
Strong content governance. Organizations need the ability to control who can access, use, share, and present specific materials.
Version control. When content changes, the field should not have to wonder which version is current.
Intelligent discovery. The more content an organization has, the more important it becomes to help users find what they actually need.
Mobile and offline access. The best content in the world isn't useful if the representative can't access it when meeting with a customer.
Usage visibility. Marketing and commercial teams need to understand which content is actually being used, and which materials are being ignored.
These capabilities aren't separate from AI – they are what make AI more useful.
The conversation around AI in life sciences sometimes creates a false choice:
Do we move quickly with AI, or do we protect compliance?
The better answer is neither.
The opportunity is to build a system where the two work together:
The result isn't simply an AI-driven sales enablement platform - it's a more intelligent content ecosystem.
AI is going to change how life sciences sales teams interact with information. But the organizations that benefit most may not be the ones that simply deploy the most AI.
They will be the organizations that combine AI with a well-governed, integrated, and trusted content foundation.
Because in life sciences, the question isn't just:
"Can a rep use AI to find an answer?"
Instead, it's:
"Is the answer correct, compliant, and trustworthy - and can we prove why and where it came from?"
That is where the next generation of sales enablement will be won. And for life sciences organizations, that may be the most important AI conversation of all.
Frequently Asked Questions
How can AI be used in life sciences sales enablement?
AI can help sales teams find, organize, summarize, and recommend relevant content. In regulated environments, AI should work from a controlled content foundation so that recommendations are based on current, approved materials.
Can AI replace MLR review?
No. AI can assist with content creation, organization, and discovery, but organizations still need their established medical, legal, and regulatory review processes.
Why is content governance important for AI-powered sales enablement?
AI is only as reliable as the information it works with. Strong content governance helps ensure that AI is working from current, approved, and appropriate information rather than outdated or uncontrolled materials.
What should life sciences companies look for in an AI-ready sales enablement platform?
Look for centralized content management, version control, permissions, approval workflows, search and discovery, analytics, mobile access, and offline capabilities. These provide the foundation for using AI responsibly and effectively.
Ready to Put Content Control at the Center of Your Field Strategy?
Learn how vablet gives life sciences marketing teams centralized control over content while giving field teams the freedom to work wherever their customers are.